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Abstract 
Background: Cerebellar degeneration is a rare and severe presentation of primary Sjögren syndrome. There are few 
case reports of cerebellar degeneration associated with different autoimmune diseases, especially with systemic lupus 
erythematosus and neuro-Behcet’s disease. There are only six patients reported worldwide to be affected by cerebel-
lar atrophy associated with primary Sjögren syndrome. In this report, we describe a patient with primary Sjögren 
syndrome who presented with ataxia due to cerebellar degeneration.
Case presentation: We report the case of a 37-year-old Chinese woman with primary Sjögren syndrome who 
presented with ataxia over 3 months associated with tremor of the limbs. Magnetic resonance imaging of the brain 
revealed bilateral cerebellar atrophy. Based on the presence of cerebellar signs with magnetic resonance imaging 
brain findings, she was diagnosed as cerebellar degeneration secondary to primary Sjögren syndrome. She was 
treated with methylprednisolone, hydroxychloroquine, and two cycles of monthly intravenous cyclophosphamide. 
Subsequently, she refused further treatment, and her neurological symptoms remained the same upon the last clinic 
review. Primary cerebellar degeneration is rarely associated with primary Sjögren syndrome. The pathogenesis of the 
neurological manifestations in primary Sjögren syndrome is unclear. Treatment involves corticosteroids and immuno-
suppressive agents with no consensus of a specific therapy for the management of primary Sjögren syndrome with 
central nervous system involvement.
Conclusions: Cerebellar degeneration is a rare presentation of primary Sjögren syndrome. Early diagnosis and treat-
ment of this condition is needed to ensure a good outcome.
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Background
Primary Sjögren syndrome (PSS) is an autoimmune 
connective tissue disease, characterized by mononu-
clear infiltration and destruction of salivary and lacri-
mal glands leading to xerostomia and xerophthalmia. It 
predominantly affects female patients between 40 and 
50 years of age [1].
SS may occur as primary or secondary to another 
connective tissue disease (mainly systemic lupus 
erythematosus, rheumatoid arthritis, or scleroderma). 
Approximately 35% of patients with primary Sjögren 
syndrome (PSS) suffer from systemic manifestations [2]. 
Neurological disorders are one of the extraglandular 
manifestations of the disease. In 25–60% of cases, the 
neurological symptoms preceded the diagnosis of PSS by 
2 years. In the remaining patients, neurological disorders 
appeared 6–8 years after diagnosis [3].
The prevalence of neurological manifestations in PSS 
varies widely from 10% to 60% [4–6]. The most com-
mon neurological complication of PSS is peripheral neu-
ropathy, particularly sensory polyneuropathy [7]. Central 
nervous system (CNS) involvement is much less common 
(2–25%) [8, 9]. Although ataxia due to PSS has also been 
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